C4X Discovery Holdings PLC Business Update (7901P)
September 05 2017 - 1:00AM
UK Regulatory
TIDMC4XD
RNS Number : 7901P
C4X Discovery Holdings PLC
05 September 2017
C4X Discovery Holdings plc
("C4XD", "C4X Discovery" or the "Company")
Business Update
5 September 2017 - C4X Discovery Holdings plc (AIM: C4XD), a
pioneering drug discovery company, today provides an update on the
Drug Discovery Engine and portfolio progress.
The company has continued to make progress towards its aim of
becoming the world's most productive drug discovery engine by
exploiting cutting edge technologies to design and create
best-in-class small-molecule candidates targeting a range of high
value therapeutic areas.
Key drug discovery programmes in addiction and inflammation have
advanced and our Taxonomy3(R) DNA-based target discovery technology
is producing novel target data in a number of commercially valuable
disease areas. These targets can be addressed through our drug
design platform including our Conformetrix and Molplex chemistry
technologies and we are in discussions with a number of potential
pharmaceutical partners which we anticipate will result in a deal
in line with our previously announced expectations.
Dr Clive Dix, CEO of C4X Discovery, said: "We continue to
develop the data package around our most advanced drug candidate,
an Orexin-1 antagonist aimed at treating addiction, and have
recently completed a study in cocaine-induced brain dopamine
elevation. Combined with our already compelling pre-clinical data
package around nicotine addiction, we are confident that our lead
programme represents a highly attractive prospect for partnering
with pharma and the initial discussions are progressing as we had
hoped.
"We are also increasingly seeing the power of our drug discovery
engine with exciting new targets identified in inflammation and
neurodegenerative diseases. These open new opportunities to develop
valuable new discovery programmes and early-stage
revenue-generating deals with the pharmaceutical industry."
--ENDS-
For further information, please contact:
C4X Discovery Holdings plc
Clive Dix, Chief Executive Officer 07801 865 803
Panmure Gordon (UK) Limited (NOMAD) 020 7886 2500
Freddy Crossley, Duncan Monteith (Corporate Finance)
Tom Salvesen (Corporate Broking)
Consilium Strategic Communications
Mary-Jane Elliott, Matthew Neal, Melissa Gardiner 0203 709
5700
About C4X Discovery
C4X Discovery aims to become the world's most productive drug
discovery engine by exploiting cutting edge technologies to design
and create best-in-class small-molecule candidates targeting a
range of high value therapeutic areas. The company's goal is to
drive returns through early-stage revenue-generating deals with the
pharmaceutical industry.
C4X Discovery has a state-of-the-art suite of proprietary
technologies across the drug discovery process. The company's
innovative DNA-based target identification platform (Taxonomy3(R))
utilises human genetic datasets to identify novel patient-specific
targets leading to greater discovery productivity and increased
probability of clinical success. This is complemented by C4XD's
novel drug design platform which comprises two innovative chemistry
technologies, Conformetrix and Molplex, that combine 4D molecular
shape analyses (based on experimental data) with best-in-class
computational chemistry. This provides new and unprecedented
insight into the behaviour of drug molecules, enabling the
production of potent selective compounds faster and more cost
effectively than the industry standard.
C4X Discovery is advancing its in-house pipeline in addiction,
diabetes and inflammation with a number of new drug candidates
identified and further progress made towards the clinic. In
selecting new targets C4X Discovery will focus on the high-value
disease areas of inflammation and neurodegeneration, and will
continue to maximise value from opportunistic areas, for example,
immuno-oncology, addiction, and diabetes.
The Company was founded as a spin-out from the University of
Manchester. It has a highly experienced management team and Board
who have delivered significant value creation within the healthcare
sector historically and have enabled C4XD to reach multiple value
inflexion points since IPO. For additional information please go
to: www.c4xdiscovery.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
UPDUGUBPBUPMGMC
(END) Dow Jones Newswires
September 05, 2017 02:00 ET (06:00 GMT)
C4x Discovery (LSE:C4XD)
Historical Stock Chart
From Apr 2024 to May 2024
C4x Discovery (LSE:C4XD)
Historical Stock Chart
From May 2023 to May 2024